1-2 of 2
Nicola Polverelli, MD PhD
Close
Sort by
Journal Articles

Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study

Robert Zeiser, PhD, Nicola Polverelli, MD PhD, Ron Ram, MD, Shahrukh K. Hashmi, MDMPH, Ronjon Chakraverty, BMBS, PhD, Mary E. D. Flowers, MD, Fitzroy Dawkins, MD, Norbert Hollaender, MD, Maanasa Gowda, PharmD, Tommaso Stefanelli, MD, Stephanie J. Lee, MDMPH, Takanori Teshima, MD, Franco Locatelli, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–24.
https://doi.org/10.1182/blood-2020-137694
Published: 2020
Journal Articles

Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with Myelofibrosis

Roberto Latagliata, MD, Ambra Di Veroli, MD, Giuseppe Alberto Palumbo, MD, Massimiliano Bonifacio, Alessandro Andriani, MD, Nicola Polverelli, MD PhD student, Malgorzata Trawinska, MD, Mario Tiribelli, MD, Barbara Anaclerico, MD, Giulia Benevolo, MD, Luca Petriccione, MD, Bruno Martino, MD, Antonia Centra, MD, Mariella D'Adda, MD, Monica Crugnola, MD, Francesco Cavazzini, MD, Micaela Bergamaschi, MD, Alessia Tieghi, MD, Adalberto Ibatici, MD, Costanza Bosi, MD, Margherita Perricone, PhD, Marco Montanaro, MD, Michele Cavo, Massimo Breccia, MD, Nicola Vianelli, MD, Francesca Palandri, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4251.
https://doi.org/10.1182/blood.V128.22.4251.4251
Published: 2016